Biotech Values

[DewDiligence]

MNTA strongly agrees with SNY’s Citizen Petition insofar as it demands that a generic Lovenox replicate all of the heparin chains in branded Lovenox rather than merely matching the molecular weight and FIIa/FXa activity of the branded drug.

Thus, SNY’s CP plays to MNTA’s competitive advantage relative to Teva and Amphastar, the other ANDA filers; if the FDA concurs with SNY’s CP, it increases the likelihood that the FDA will approve only the generic from NVS/MNTA rather than approving multiple generics.